Skip to main content
. Author manuscript; available in PMC: 2014 Sep 22.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Apr 14;(4):CD008042. doi: 10.1002/14651858.CD008042.pub2

Comparison 1. Zolmitriptan 5 mg versus placebo.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Participants with headache relief at 30 minutes 3 457 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [1.15, 1.78]
  1.1 Oral 1 229 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.96, 1.63]
  1.2 Nasal spray 2 228 Risk Ratio (M-H, Fixed, 95% CI) 1.74 [1.20, 2.51]
2 Participants pain-free at 30 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
  2.1 Nasal spray 2 228 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [1.12, 2.90]
3 Participants with headache relief at 15 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
  3.1 Nasal spray 2 228 Risk Ratio (M-H, Fixed, 95% CI) 2.15 [0.99, 4.67]
4 Participants pain-free at 15 minutes 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
  4.1 Nasal spray 2 228 Risk Ratio (M-H, Fixed, 95% CI) 2.60 [0.80, 8.46]
5 Participants using rescue medication 3 457 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.55, 0.91]
  5.1 after 30 minutes 2 355 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.52, 0.90]
  5.2 after 60 minutes 1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.47, 1.39]
6 Participants with any adverse event 2 331 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [1.15, 2.77]